144 related articles for article (PubMed ID: 10842400)
1. Current perspectives on interventional treatment strategies in diabetic patients with coronary artery disease.
Kornowski R; Lansky AJ
Catheter Cardiovasc Interv; 2000 Jun; 50(2):245-54. PubMed ID: 10842400
[TBL] [Abstract][Full Text] [Related]
2. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.
Bhatt DL; Marso SP; Lincoff AM; Wolski KE; Ellis SG; Topol EJ
J Am Coll Cardiol; 2000 Mar; 35(4):922-8. PubMed ID: 10732889
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
[TBL] [Abstract][Full Text] [Related]
5. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
[TBL] [Abstract][Full Text] [Related]
6. Management of coronary artery disease: therapeutic options in patients with diabetes.
Hammoud T; Tanguay JF; Bourassa MG
J Am Coll Cardiol; 2000 Aug; 36(2):355-65. PubMed ID: 10933343
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.
Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC
Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381
[TBL] [Abstract][Full Text] [Related]
8. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Roffi M; Moliterno DJ; Meier B; Powers ER; Grines CL; DiBattiste PM; Herrmann HC; Bertrand M; Harris KE; Demopoulos LA; Topol EJ;
Circulation; 2002 Jun; 105(23):2730-6. PubMed ID: 12057986
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
[TBL] [Abstract][Full Text] [Related]
10. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
11. Optimizing percutaneous coronary revascularization in diabetic women: analysis from the EPISTENT trial.
Cho L; Marso SP; Bhatt DL; Topol EJ
J Womens Health Gend Based Med; 2000 Sep; 9(7):741-6. PubMed ID: 11025866
[TBL] [Abstract][Full Text] [Related]
12. Late outcomes after intervention of vein grafts in diabetics with abciximab use.
Applegate RJ; Upadhya B; Little WC; Xenakis M; Gandhi SK; Baki TT; Kahl FR; Kutcher MA
Int J Cardiol; 2006 Jul; 111(1):136-41. PubMed ID: 16226815
[TBL] [Abstract][Full Text] [Related]
13. Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology.
Reginelli JP; Bhatt DL
J Invasive Cardiol; 2002 Dec; 14 Suppl E():2E-10E; quiz 11E. PubMed ID: 12668857
[TBL] [Abstract][Full Text] [Related]
14. Potent complementary clinical benefit of abciximab and stenting during percutaneous coronary revascularization in patients with diabetes mellitus: results of the EPISTENT trial.
Lincoff AM
Am Heart J; 2000 Feb; 139(2 Pt 2):S46-52. PubMed ID: 10650316
[No Abstract] [Full Text] [Related]
15. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
[TBL] [Abstract][Full Text] [Related]
16. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
[TBL] [Abstract][Full Text] [Related]
17. Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing.
Lincoff AM; LeNarz LA; Despotis GJ; Smith PK; Booth JE; Raymond RE; Sapp SK; Cabot CF; Tcheng JE; Califf RM; Effron MB; Topol EJ
Ann Thorac Surg; 2000 Aug; 70(2):516-26. PubMed ID: 10969673
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
[TBL] [Abstract][Full Text] [Related]
19. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
[TBL] [Abstract][Full Text] [Related]
20. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions.
Cura FA; Bhatt DL; Lincoff AM; Kapadia SR; L'Allier PL; Ziada KM; Wolski KE; Moliterno DJ; Brener SJ; Ellis SG; Topol EJ
Circulation; 2000 Jul; 102(1):28-34. PubMed ID: 10880411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
